12 thoughts on “D90 – Ludwick

    1. It’s hard to say. We were only able to only run one experiment with two vials of each compound to compare with. Due to such low trials and such little data to compare, it’s hard to say if repetition would yield totally different or the same results. Hopefully, it would yield very similar results so we could decrease variability.

  1. If you were given more time, do you think you would end up getting a higher percent of survival eventually?

    1. I think if we were to be able to modify our dosage of the Myricetin compound initially, we could get a “hit” from the same dilutions of Colchicine we used initially. I don’t necessarily think replication of these certain vials would produce results so drastic from our initial results as to produce a “hit.”

  2. If you were given more time, do you think your results would show any significant change?

    1. I think replication of this experiment wouldn’t necessarily produce a drastic enough change to produce a “hit,” but I do think replication would be able to solidify our conclusion more by decreasing variability in results. This would also provide more insight into the future directions of testing the compound.

  3. Would you expect Myricetin to interact differently with chemotherapeutics other than the Colchicine you utilized? Or does it behave similarly with any chemotherapeutic?

    1. Great question! Colchicine is no longer used as a chemotherapeutic due to its toxicity. One of the theories we had for the high variability is that Colchicine could have degraded the Myricetin compound to an extent and altered its effectiveness. I think that Myricetin could be more effective with approved chemotherapeutics because of the decreased toxicity.

  4. Amazing presentation and poster! Were you able to determine if Myricetin is additive or synergistic? If not, what future steps do you think you could take to find this out?

    1. Thank you, Corbin! Unfortunately, because of the time restriction and only being able to run one experiment with no replicates, we couldn’t fully conclude if Myricetin is additive or synergistic. Although, the evidence does suggest that Myricetin could have an additive effect, as each vial of Colchicine with the Myricetin compound had a lower percent survival than the vials with Colchicine alone. To test this we would like to first run duplicates of our experiments to reduce variability. After interpreting those results, and if we saw definite curves, we could then test lower doses of Colchicine, or run a TD50 to see Myricetin’s effectiveness and test different concentrations of Myricetin to see its additive aspect in full effect.

  5. You said one of your future experiments would be to test a lower concentration of Colchicine to try and get a “hit.” How did you choose the concentration for your initial tests?

    1. We used the initial concentration of Colchicine used as the positive control from the Myricetin dose-response experiment. Because Colchicine is so toxic, we made a 1:10 dilution from the 50 mg/mL stock with four dilutions tested. We think these concentrations of Colchicine are still a little too toxic for the Myricetin, so we would like to test lower doses in order to see its effectiveness.

Leave a Reply